Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes

WHAT IS KNOWN AND OBJECTIVE: In recent years, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) including once‐weekly (QW) formulations have been incorporated into type 2 diabetes (T2D) clinical guidelines, making it essential that pharmacists and healthcare professionals (HCPs) have a clear und...

Descripción completa

Detalles Bibliográficos
Autor principal: Trujillo, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540535/
https://www.ncbi.nlm.nih.gov/pubmed/32910487
http://dx.doi.org/10.1111/jcpt.13225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540535/
https://www.ncbi.nlm.nih.gov/pubmed/32910487
http://dx.doi.org/10.1111/jcpt.13225

Ejemplares similares